Dr. Beth Meneley, DAOM, L.Ac.

With over 18 years dedicated to advancing medical science, Dr. Ethan Parker leads Carelis’s clinical research initiatives with a passion for turning innovative ideas into real-world healthcare solutions. His expertise lies in designing and managing cutting-edge clinical trials that ensure the safety, efficacy, and regulatory compliance of new diagnostics and therapies.

Dr. Parker’s approach emphasizes collaboration across disciplines—from bioinformatics to patient care—to accelerate the development of personalized medicine tools that improve outcomes. He is committed to translating complex scientific insights into actionable strategies that empower healthcare providers and patients alike.

Whether overseeing biomarker discovery projects or guiding medical device testing, Dr. Parker prioritizes precision, transparency, and ethical rigor. Patients and partners benefit from his unwavering dedication to evidence-based innovation and his skill in navigating the evolving landscape of clinical research.

What Dr. Parker Can Help With:

• Designing and managing clinical trials that meet stringent regulatory standards
• Identifying and validating novel biomarkers for early diagnosis and treatment monitoring
• Overseeing the development and testing of cutting-edge medical devices
• Translating research findings into actionable clinical solutions
• Collaborating with cross-functional teams to drive innovation and improve healthcare delivery

His Approach:

• Precision and Accuracy: Ensuring diagnostic tools are reliable and deliver timely results
• Ethical Leadership: Committing to transparency, patient safety, and compliance throughout research
• Interdisciplinary Collaboration: Bridging scientific disciplines and clinical practice for holistic solutions
• Patient Empowerment: Focusing on tools and methods that enhance personalized care and patient outcomes
• Continuous Learning: Staying at the forefront of emerging technologies and medical research

Dr. Parker’s dedication to advancing clinical research and his ability to navigate the complex regulatory landscape make him an invaluable asset to Carelis and its partners. He is deeply committed to improving lives through science, technology, and compassionate care.